Anti-HER2/HER3 Dendritic Cell Vaccine is under clinical development by Northwest Biotherapeutics and currently in Phase II for Metastatic Brain Tumor. According to GlobalData, Phase II drugs for Metastatic Brain Tumor have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Anti-HER2/HER3 Dendritic Cell Vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anti-HER2/HER3 Dendritic Cell Vaccine overview
The therapeutic candidate is under development for the treatment of untreated brain metastasis caused by HER2 positive breast cancer and triple negative breast cancer. The therapeutic candidate comprise of dendritic cells. It is administered by intradermal route. It acts by targeting HER2 and HER3.
Northwest Biotherapeutics overview
Northwest Biotherapeutics (NW Bio) is a development-stage biotechnology company. It develops personalized immune therapies for cancer treatment. The company uses its proprietary DCVax platform technology, which uses activated dendritic cells (DCs) to harness a patient’s immune system to target and attack cancer cells. Its product pipeline includes DCVax-L, for the treatment of glioblastoma multiforme (GBM), an aggressive brain cancer; DCVax-Direct, for the treatment of various inoperable solid tumors; and DCVax-Prostate, for the treatment of late-stage prostate cancer. NW Bio is headquartered in Bethesda, Maryland, the US.
For a complete picture of Anti-HER2/HER3 Dendritic Cell Vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
